中新网北京1月28日电 (记者 欧阳开宇)此间发布的一份研究报告表明，中国生物技术药物在医药市场所占比重不足，发展亟待提速。

Beijing Beijing January and report (Reporter OuYangKaiYu)Here issued a research report shows that,Chinese biotech drugs in the medical market lack of proportion,Development speed to be.

　　中国外商投资企业协会药品研制和开发行业委员会与美国全球生物技术工业组织28日在北京共同发布的这份报告显示，近年来，全球医药市场的发展重心正在逐步从小分子化学药转向生物技术药，后者在全球医药市场的比重从2006年的13%攀升至2010年的17%。

China association of enterprises with foreign investment of drug research and development industry committee and the United States global biotechnology industry organization and in Beijing, jointly issued report shows,In recent years,The global pharmaceutical market development center of gravity is gradually from molecular chemical medicine to biotech drugs,The latter in the global pharmaceutical market proportion rising from 13% in 2006 to 17% in 2010.

　　“中国近五年来生物技术药的比重仅停留在5%左右。”这份由波士顿咨询公司协助撰写的《在中国打造世界领先的创新型生物技术药物产业》研究报告说。

"China nearly five years the proportion of biotech drugs only stay in 5%."By the Boston consulting company assist writing[In China make the world's leading innovative biotech drugs industry]The report says.

　　报告称，尽管一些发达国家在生物技术药物方面已取得领先优势，中国仍有望打造世界级的创新型生物技术药物产业。

The report says,Although some developed countries in the biotech drugs has the lead,China still is expected to create a world-class innovative biotech drugs industry.

　　美国全球生物技术工业组织高级副总裁约瑟夫·戴梦德认为，生物技术药物产业的发展壮大需要有利的政策环境，需要同时从推动产业能力的提升和拉动市场需求两方面着手，缺一不可。

The United States global biotechnology industry organization senior vice President, Joseph DaiMengDe think,Biotech drugs industry development need favorable policy environment,At the same time to promote the industry from the ability of ascension and pull the market demand two aspects,integral.

　　有专家指出，官方层面应针对创新型生物药建立严谨严格的，以大量科学数据为依据为基础的监管审批制度和严格有效的执行体系，覆盖全生产过程的监测系统，严格监管不良免疫反应，与国际接轨。

The expert points out,The official level should be aimed at innovative biological medicine establish rigorous strict,With a great number of scientific data based on the basis of the examination and approval system and strict supervision of the implementation of effective system,Cover the whole production process monitoring system,Strict supervision bad immune response,And international.

　　研究报告发布会主办方代表卓永清说，国际创新型生物药物企业愿意与政府、研究机构以及国内企业加强合作，共同为建立激励创新和促进产业快速可持续发展的生态体系而努力。(完)

Study the host representative conference ZhuoYongQing said,International innovative biological medicine enterprise are willing to work with the government/Research institutions and domestic enterprises to strengthen cooperation,Together for establishing incentive innovation and promote the sustainable development of industry fast ecological system and efforts.(finish)